Literature DB >> 24993158

Cellular and molecular mechanisms of bone damage and repair in inflammatory arthritis.

Catherine Swales1, Afsie Sabokbar2.   

Abstract

Bone remodelling relies on tightly controlled cycles of bone resorption and formation, mediated by osteoclasts and osteoblasts, respectively. The past two decades have seen a huge increase in our understanding of immune modulation and disruption of bone homeostasis in rheumatic diseases; identification of the molecular pathways responsible for accelerated bone loss in such conditions has given rise to potential novel therapeutic targets. Most recently, the role of microRNAs in inflammatory and noninflammatory bone loss raises the intriguing possibility that modification of cellular protein translation could also be a treatment strategy for bone damage.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24993158     DOI: 10.1016/j.drudis.2014.06.025

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

Review 1.  Adipokines in bone disease.

Authors:  Elena Neumann; Susann Junker; Georg Schett; Klaus Frommer; Ulf Müller-Ladner
Journal:  Nat Rev Rheumatol       Date:  2016-04-15       Impact factor: 20.543

2.  Bone marrow mesenchymal stem cells improve bone erosion in collagen-induced arthritis by inhibiting osteoclasia-related factors and differentiating into chondrocytes.

Authors:  Jinfang Gao; Gailian Zhang; Ke Xu; Dan Ma; Limin Ren; Jingjing Fan; Jianwen Hou; Jian Han; Liyun Zhang
Journal:  Stem Cell Res Ther       Date:  2020-05-07       Impact factor: 6.832

3.  Serum Heme Oxygenase-1 and BMP-7 Are Potential Biomarkers for Bone Metabolism in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.

Authors:  Tong-Ling Yuan; Jin Chen; Yan-Li Tong; Yan Zhang; Yuan-Yuan Liu; James Cheng-Chung Wei; Yi Liu; Yi Zhao; Martin Herrmann
Journal:  Biomed Res Int       Date:  2016-05-26       Impact factor: 3.411

4.  Puerarin improves graft bone defect through microRNA‑155‑3p‑mediated p53/TNF‑α/STAT1 signaling pathway.

Authors:  Yang Zhou; Hongyu Lian; Kexin Liu; Deli Wang; Xuelian Xiu; Zhang Sun
Journal:  Int J Mol Med       Date:  2020-05-06       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.